RION Partners with Lonza to Scale Commercial Production of Platelet-Derived Exosome Therapeutics
Key Insights
RION (search) has engaged Lonza to provide cGMP manufacturing and technical support for commercial-scale production of its Purified Exosome Product (search) (PEP) drug substance at Lonza's Houston facility.
The collaboration leverages RION (search)'s proprietary biomanufacturing platform for scaled production of platelet-derived exosomes with Lonza's global infrastructure and extracellular vesicles expertise.
PEP is formulated as a shelf-stable lyophilized powder with immunomodulatory, anti-inflammatory and tissue regenerative properties for multiple therapeutic indications.
RION (search), a commercial and clinical-stage regenerative medicine company, has announced a strategic collaboration with Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), to scale commercial production of its platelet-derived exosome therapeutics. The partnership will provide cGMP manufacturing and technical support for commercial-scale production of RION's Purified Exosome Product (search) (PEP) drug substance for late phase clinical supply and beyond.
Manufacturing Partnership Details
Under the terms of the agreement, Lonza will manufacture PEP drug substance at its manufacturing facility in Houston, Texas. RION (search) will leverage Lonza's world-leading, state-of-the-art extracellular vesicles expertise and capabilities to operationalize its proprietary biomanufacturing process at scale.
RION (search) has developed a proprietary biomanufacturing platform enabling scaled production of platelet-derived exosomes, which allows for the advancement of the company's pipeline of exosome-based therapeutics across multiple indications.
Therapeutic Platform Characteristics
PEP is an exosome-based therapeutic platform candidate with immunomodulatory, anti-inflammatory and tissue regenerative properties, formulated as a shelf-stable lyophilized powder. The stabilized regenerative exosomes promote tissue repair and can be administered through multiple routes, enabling use across a broad set of indications.
RION (search) is advancing clinical programs in advanced tissue regeneration (search), immune-mediated dermatology diseases (search), musculoskeletal disease (search), pulmonary disease (search), cardiovascular health (search) and women's health.
Executive Perspectives
"This collaboration with Lonza ensures that our proprietary exosome manufacturing platform can be scaled to meet clinical and future commercial demand," said Atta Behfar, Cofounder and CEO of RION (search). "RION's breakthrough in exosome biomanufacturing now paired with Lonza's global infrastructure allows us to bring this biologics-based innovation to patients rapidly and reliably, while staying true to our mission of affordable access."
Davide Zocco, Commercial Development Head for Exosomes and mRNA Technologies, Specialized Modalities at Lonza, added: "We are pleased to support RION (search)'s groundbreaking work in exosome-based therapies. Through our world-leading capabilities in exosome development, characterization, and manufacturing, we enable our customers to progress their innovative therapies efficiently and reliably. Through our collaboration with RION, we will apply our expertise to support the manufacture of PEP drug substance, aiming to help accelerate the availability of innovative treatments to patients worldwide."